155 related articles for article (PubMed ID: 23134625)
1. Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naïve patients prescribed efavirenz compared to atazanavir/ritonavir.
Gotti D; Cesana BM; Albini L; Calabresi A; Izzo I; Focà E; Motta D; Bellagamba R; Fezza R; Narciso P; Sighinolfi L; Maggi P; Brianese N; Quiros-Roldan E; Guaraldi G; Torti C
HIV Clin Trials; 2012; 13(5):245-55. PubMed ID: 23134625
[TBL] [Abstract][Full Text] [Related]
2. Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.
Casado JL; de Los Santos I; Del Palacio M; García-Fraile L; Pérez-Elías MJ; Sanz J; Moreno S
HIV Clin Trials; 2013; 14(1):1-9. PubMed ID: 23372109
[TBL] [Abstract][Full Text] [Related]
3. A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz.
Albini L; Cesana BM; Motta D; Focà E; Gotti D; Calabresi A; Izzo I; Bellagamba R; Fezza R; Narciso P; Sighinolfi L; Maggi P; Quiros-Roldan E; Manili L; Guaraldi G; Lapadula G; Torti C
J Acquir Immune Defic Syndr; 2012 Jan; 59(1):18-30. PubMed ID: 21992924
[TBL] [Abstract][Full Text] [Related]
4. Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.
Tremblay C; Trottier B; Rachlis A; Baril JG; Loutfy M; Lalonde R; Sampalis JS; Boulerice F
HIV Clin Trials; 2011; 12(3):151-60. PubMed ID: 21684855
[TBL] [Abstract][Full Text] [Related]
5. Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials.
Carey D; Amin J; Boyd M; Petoumenos K; Emery S
J Antimicrob Chemother; 2010 Sep; 65(9):1878-88. PubMed ID: 20554568
[TBL] [Abstract][Full Text] [Related]
6. A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.
Dejesus E; Mills A; Bhatti L; Conner C; Storfer S
Int J Clin Pract; 2011 Dec; 65(12):1240-9. PubMed ID: 21999631
[TBL] [Abstract][Full Text] [Related]
7. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
8. Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study.
Dai L; Liu A; Zhang H; Wu H; Zhang T; Su B; Shao Y; Li J; Ye J; Scott SR; Mahajan SD; Schwartz SA; Yu H; Sun L
Curr HIV Res; 2019; 17(5):324-334. PubMed ID: 31654514
[TBL] [Abstract][Full Text] [Related]
9. Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
Calza L; Trapani F; Salvadori C; Magistrelli E; Manfredi R; Colangeli V; Di Bari MA; Borderi M; Viale P
Scand J Infect Dis; 2013 Feb; 45(2):147-54. PubMed ID: 22991923
[TBL] [Abstract][Full Text] [Related]
10. The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.
Josephson F; Andersson MC; Flamholc L; Gisslén M; Hagberg L; Ormaasen V; Sönnerborg A; Vesterbacka J; Böttiger Y
Eur J Clin Pharmacol; 2010 Apr; 66(4):349-57. PubMed ID: 19967342
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.
Elion R; Cohen C; Ward D; Ruane P; Ortiz R; Reddy YS; Ebrahimi R; McColl D; Kearney B; Fisher A; Flaherty J;
HIV Clin Trials; 2008; 9(4):213-24. PubMed ID: 18753116
[TBL] [Abstract][Full Text] [Related]
12. Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study.
Elion R; Dejesus E; Sension M; Berger D; Towner W; Richmond G; St Clair M; Yau L; Ha B;
HIV Clin Trials; 2008; 9(3):152-63. PubMed ID: 18547902
[TBL] [Abstract][Full Text] [Related]
13. Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine.
Honda M; Ishisaka M; Ishizuka N; Kimura S; Oka S;
Intern Med; 2011; 50(7):699-705. PubMed ID: 21467701
[TBL] [Abstract][Full Text] [Related]
14. Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda.
Buchacz K; Weidle PJ; Moore D; Were W; Mermin J; Downing R; Kigozi A; Borkowf CB; Ndazima V; Brooks JT
J Acquir Immune Defic Syndr; 2008 Mar; 47(3):304-11. PubMed ID: 18398971
[TBL] [Abstract][Full Text] [Related]
15. Efavirenz outperforms boosted atazanavir among treatment-naive HIV-1-infected persons in routine clinical care.
Taniguchi T; Grubb JR; Nurutdinova D; Önen NF; Shacham E; Donovan M; Overton ET
J Int Assoc Provid AIDS Care; 2013; 12(2):138-41. PubMed ID: 23269514
[TBL] [Abstract][Full Text] [Related]
16. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
Soriano V; Arastéh K; Migrone H; Lutz T; Opravil M; Andrade-Villanueva J; Antunes F; Di Perri G; Podzamczer D; Taylor S; Domingo P; Gellermann H; de Rossi L;
Antivir Ther; 2011; 16(3):339-48. PubMed ID: 21555816
[TBL] [Abstract][Full Text] [Related]
17. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.
Quercia R; Roberts J; Martin-Carpenter L; Zala C
Clin Drug Investig; 2015 Mar; 35(3):211-9. PubMed ID: 25637061
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients.
Horberg M; Klein D; Hurley L; Silverberg M; Towner W; Antoniskis D; Kovach D; Mogyoros M; Blake W; Dobrinich R; Dodge W
HIV Clin Trials; 2008; 9(6):367-74. PubMed ID: 19203902
[TBL] [Abstract][Full Text] [Related]
19. Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results.
Castagna A; Spagnuolo V; Galli L; Vinci C; Nozza S; Carini E; D'Arminio Monforte A; Montella F; Antinori A; Di Biagio A; Rusconi S; Lazzarin A;
AIDS; 2014 Sep; 28(15):2269-79. PubMed ID: 25058680
[TBL] [Abstract][Full Text] [Related]
20. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]